Ciphergen Appoints Steve Lundy as Senior Vice President of Sales and Marketing
May 15 2007 - 5:47PM
PR Newswire (US)
FREMONT, Calif., May 15 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) today announced the appointment of
Steve Lundy as Senior Vice President of Sales and Marketing. Mr.
Lundy brings nearly 20 years of experience leading high growth
sales and marketing initiatives in the diagnostics industry.
"Steve's impressive track record of successfully commercializing
molecular diagnostic tests will be invaluable as we prepare for the
launch and commercialization of several high-value tests," said
Gail S. Page, President and CEO of Ciphergen. "His experience
developing marketing strategies and building commercial teams will
help us to grow our diagnostics business." Mr. Lundy joins
Ciphergen Biosystems from GeneOhm, a division of BD Diagnostics,
where he served as Vice President of Sales and Marketing since
2003. BD acquired GeneOhm for $230 million in February 2006. While
at GeneOhm, he successfully led the commercial launch of several
novel molecular diagnostic assays including the first molecular
test for Methicillin Resistant Staphylococcus Aureus (MRSA). In
addition he helped raise $30 million in venture capital. From 2002
to 2003, Mr. Lundy served as Vice President of Marketing for
Esoterix, Inc., which was acquired by Laboratory Corporation of
America, and led the commercial integration and re-branding of the
numerous reference labs acquired by Esoterix. Prior to Esoterix, he
was Marketing Director, Molecular Diagnostics and Critical Care
Testing at Bayer Diagnostics Corporation and had marketing
responsibility for a $100 million of business in the fastest
growing business segments. "I am excited to be joining Ciphergen at
this critical phase in its development as we gear up for the launch
of new products," said Mr. Lundy. "My experience in growing
successful diagnostics businesses and bringing new assays to the
marketplace will help Ciphergen achieve its mission of helping
physicians diagnose, treat and improve outcomes for patients." Mr.
Lundy holds a B.S. in Education from the United States Air Force
Academy. His appointment to Senior Vice President of Sales and
Marketing will be effective May 16, 2007. About Ciphergen Ciphergen
Biosystems, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help
physicians diagnose, treat and improve outcomes for patients.
Ciphergen, along with its prestigious scientific collaborators, has
ongoing diagnostic programs in oncology, cardiology and women's
health with an initial focus in ovarian cancer. Based in Fremont,
California, more information about Ciphergen can be found on the
Web at http://www.ciphergen.com/. Safe Harbor Statement This news
release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed
below and others that can be found in Ciphergen's Form 10-K for the
year ended Dec. 31, 2006, and in Ciphergen's periodic reports on
Form 10-Q and Form 8-K. Ciphergen is providing this information as
of the date of this news release and does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise. The scientific information discussed in this news
release is preliminary and investigative. No forward-looking
statement can be guaranteed and actual results may differ
materially from those Ciphergen projects. Discovery or
identification of new protein biomarkers cannot be guaranteed and
movement beyond the clinical validation process to a test that
successfully screens patients for ovarian cancer is uncertain;
consequently, there can be no guarantee that the identification of
potential diagnostic markers will be successful or be an
appropriate basis for a commercially available diagnostic kit for
screening ovarian cancer. DATASOURCE: Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers, Investor Relations of Ciphergen
Biosystems, Inc., +1-510-505-2233; Lori Murray, Media of WeissComm
Partners, +1-415-946-1070, for Ciphergen Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024